Most nutraceutical and dietary supplement manufacturers don’t think of themselves as doing R&D. Yet every day, teams are solving formulation problems, managing ingredient instability, and adapting products to meet clean-label and regulatory demands.
From a CRA perspective, that work often qualifies as SR&ED experimental development, and it can represent a significant, missed tax credit opportunity.
At Ayming Canada, we work with supplement manufacturers who are surprised to learn just how much of their day-to-day innovation is eligible under SR&ED.
Formulation, Bioavailability, and Ingredient Interaction
SR&ED in nutraceutical manufacturing usually starts with one simple question: Will this formulation actually work as intended?
Bioavailability targets, stability requirements, sensory constraints, and regulatory limits introduce real technological uncertainty. Published research and supplier specifications rarely explain how specific actives will behave together in a finished dose form.
When your team systematically tests excipient systems, compares capsules versus tablets or powders, or measures degradation over time, they are doing more than routine formulation. They are resolving unknowns through experimentation, which is exactly what CRA recognizes under SR&ED.
Stability, Shelf Life, and Packaging Constraints
Many SR&ED claims emerge after a product “should” work but doesn’t. Potency loss, oxidation, moisture sensitivity, or ingredient separation often force manufacturers back into testing mode.
Controlled stability studies, accelerated aging tests, and packaging trials (HDPE versus glass, blister packs versus bottles) are not marketing exercises. They are technical investigations designed to preserve efficacy and quality. When clean-label requirements remove traditional stabilizers, the uncertainty increases, and the SR&ED opportunity grows.
Novel Delivery Systems and Advanced Technologies
As the market shifts toward enhanced delivery formats, manufacturers are adopting liposomal systems, microencapsulation, delayed-release mechanisms, and enteric coatings. The challenge is not access to the technology, but whether it performs reliably within a specific formulation and manufacturing process.
Experimental trials adjusting coating thickness, release timing, or encapsulation parameters often involve multiple iterations and failures. These projects represent strong SR&ED candidates because outcomes cannot be predicted in advance using existing knowledge.
Manufacturing Scale-Up and Process Optimization
One of the most overlooked SR&ED areas is scale-up. A formulation that performs well at bench or pilot scale can behave very differently in full production due to heat, shear forces, compression pressure, or mixing dynamics.
When manufacturers run process trials, modify equipment configurations, investigate batch failures, or develop new SOPs to maintain consistency, they are resolving manufacturing uncertainties. CRA explicitly supports this type of work under SR&ED, yet it is frequently missed or underclaimed.
Powder Flow, Compression, and Encapsulation Challenges
Issues with flowability, compression, or encapsulation are often treated as operational headaches rather than SR&ED opportunities. In reality, experimental blending methods, granulation trials, particle size adjustments, and compression force testing involve structured experimentation.
When results are analyzed and refinements are made iteratively, these activities meet CRA’s definition of experimental development.
Probiotics, Live Cultures, and High-Risk Formulations
For probiotic and live-culture products, uncertainty is unavoidable. Manufacturers must determine whether organisms can survive processing, storage, and the digestive environment.
Testing strain survivability, experimenting with protective carriers, and monitoring CFU counts over time are high-risk, high-value SR&ED activities. When documented correctly, these projects often support robust claims.
Why Nutraceutical Manufacturers Partner with Ayming Canada
SR&ED Tax Credit and Investment Tax Credits (ITCs) are not just about filling out forms, they’re about telling your technical and manufacturing story in a way CRA understands and accepts.
Ayming Canada brings 40 years of experience, a 98.5% success rate, and deep expertise in both R&D and manufacturing. We help nutraceutical and dietary supplement manufacturers uncover eligible SR&ED work. This includes formulation development, stability testing, process scale-up, and advanced delivery technologies. We also identifying Investment Tax Credit opportunities tied to equipment, automation, and facility expansion.
If your business is innovating, scaling production, or upgrading manufacturing processes to meet regulatory or clean-label requirements, you are likely eligible for both SR&ED and ITCs. The only question is whether you’re capturing the full value of your innovation and investment.
Talk to Ayming Canada and unlock the full spectrum of government funding and tax incentives available to support your nutraceutical innovation and manufacturing growth.
Contact us today!
One of our experts will be in touch shortly.
